A Closer Look

**SUMMARY**
A Model 6860 magnet may be used with all Boston Scientific ICDs and CRT-Ds to temporarily inhibit tachy therapy. This article describes how to perform this function. Magnet application will prevent delivery of tachy therapy while the magnet remains positioned (magnet features must be enabled).

**Products Referenced**
All Boston Scientific ICDs and CRT-Ds

Products referenced herein may not be approved in all geographies. For comprehensive information on device operation, reference the full instructions for use found at: www.bostonscientific.com/cardiac/defibrillator/international manuals.html.

**CAUTION:** Laws restrict this device to sale by or on the order of a physician. Indications, contraindications, precautions and warnings can be found with product labeling.

All graphics produced by Boston Scientific Corporation, unless otherwise noted.

**Contact Information**

**Americas**
(Caribbean, and Central, North, and South America)
www.bostonscientific.com

**Technical Services**
LATITUDE® Clinician Support
1.800.CARDIAC (227-3422)
+1 651.582.4500

Patient Services
1.866.484.3268

**Europe, Middle East, Africa**

Technical Services
+32 2 416 7222
eurtechservice@bsci.com

LATITUDE Clinician Support
latitude.europe@bsci.com

**Asia Pacific**

Technical Services
+61 2 8063 8299
aptechservice@bsci.com

LATITUDE Clinician Support
latitude.asiapacific@bsci.com
japan.latitude@bsci.com (Japan)

© 2013 by Boston Scientific Corporation or its affiliates. All Rights Reserved.

---

**Using a Magnet to Inhibit Tachy Therapy in Boston Scientific ICDs and CRT-Ds**

A magnet may be used with all Boston Scientific ICDs and CRT-Ds to temporarily inhibit tachy therapy, assuming the device has been previously programmed to respond to magnet application.

**IMPORTANT:** A small subset of Boston Scientific devices* includes an additional magnet function which can be used to toggle Tachycardia Therapy between ‘Off’ and ‘Monitor + Therapy’. If the device is in this subset or if the model is unknown, contact Technical Services for additional magnet use information prior to magnet application.

*PRIZM: 1850, 1851, 1852, 1853, 1855, 1856, 1857, and 1858; PRIZM 2: 1860, 1861; VITALITY DS T125, T135; VITALITY EL: T127

**Determine if Magnet Functions are Enabled**
To determine if the device has been programmed to respond to magnet application, position a doughnut magnet (Model 6860) over the device and listen for tones.

If tones ARE heard, magnet functions are enabled.

If tones ARE NOT heard:
- Magnet functions are not enabled (i.e., a programmer is required to program magnet functions On in order to use a magnet to inhibit therapy), or
- The magnet is not correctly positioned over the device, or
- The device was not manufactured by Boston Scientific.

**Using a Magnet to Temporarily Inhibit Tachy Therapy**

To inhibit tachy therapy, position a doughnut magnet (Model 6860) over the device. While the magnet is in place and tones are heard, the tachyarrhythmia detection process continues, but therapy will not be delivered as long as the magnet remains correctly positioned. Two to three seconds following magnet removal, the device will return to the programmed Tachy Therapy Mode and no tones will be heard.

**NOTES:**
- If any tones continue more than three seconds after the magnet has been removed, contact Technical Services.
- If tones change (from beeping to continuous or vice versa) after 30 seconds of magnet application, this model is within the select group of Boston Scientific defibrillators in which a doughnut magnet may also be used to toggle Tachycardia Therapy Mode between “Monitor + Therapy” and “Off” (discussed in the box above).

To program Tachy mode back to “Monitor + Therapy”:
- Remove the magnet for at least 2 seconds.
- Reapply until the tones change to beeping (approximately 30 seconds).
- Remove the magnet.

Contact Technical services for further information about this feature.
Figure 1. Using a Magnet to Temporarily Inhibit Tachy Therapy (available in all Boston Scientific ICDs and CRT-Ds)

**NOTES:**
- Contact your local representative or Technical Services with questions regarding magnet use.
- If the device is programmed to Electrocautery Protection Mode or Off-Electrocautery, magnet application will have no impact on Tachy therapy delivery. Tones will be determined by device programming (i.e., electrocautery mode) rather than magnet application and may not match those described in this ACL.
- Device responses described are dependent upon available device features and programming.
- Unlike pacemakers, magnet application does not affect bradycardia pacing in an ICD or CRT-D.
- Advise patients to have their device checked whenever tones are heard.
- **Boston Scientific issued a Product Advisory dated June 23, 2005, regarding important information for specific serialized devices within the following Models: H170/H173/H175/H177/H179/H190/H195/ H197/H199/M155/M159/ M170/M175/M177/M179/H230/H235/H239. We recommended that physicians consider programming the Enable Magnet Use feature “OFF” in these devices. A programmer software upgrade has since been released, which identifies affected devices and warns clinicians when they attempt to enable magnet features in these devices. A serialized device lookup tool to determine if a device is affected by this product advisory is available at [www.bostonscientific.com](http://www.bostonscientific.com) or [www.bostonscientific-international.com](http://www.bostonscientific-international.com).
CRT-D Systems from Boston Scientific CRM (PUNCTUA, ENERGEN and INCEPTA)

Indications and Usage
The PUNCTUA™, ENERGEN™, and INCEPTA™ Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) are indicated for patients with heart failure who receive stable optimal pharmacologic therapy (OPT) for heart failure and who meet any one of the following classifications:
- Moderate to severe heart failure (NYHA Class III-IV) with EF ≤ 35% and QRS duration ≥ 120 ms
- Left bundle branch block (LBBB) with QRS ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class III) ischemic or nonischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure

Contraindications
There are no contraindications for this device.

Warnings
Read the product labeling thoroughly before implating the pulse generator to avoid damage to the system. For single patient use only. Do not reuse, repurpose, or resterilize. Program the pulse generator Tachy Mode to Off during implant, explant or postmortem procedures. Always have external defibrillator protection available during implant and electrophysiologic testing. Ensure that an external defibrillator and medical personnel skilled in CPR are present during post-implant device testing. Advise patients to seek medical guidance before entering environments that could adversely affect the operation of the active implantable medical device, including areas protected by a warning notice that prevents entry by patients who have a pulse generator. Do not expose a patient to MRI scanning. Do not subject a patient with an implanted pulse generator to diathermy. Do not use atrial-tracking modes in patients with chronic refractory atrial tachyarrhythmias. Do not use atrial-only modes in patients with heart failure. LV lead dislodgment to a position near the atria can result in atrial oversensing and LV pacing inhibition. Physicians should use medical discretion when implanting this device in patients who present with slow VT. Do not kink, twist or braid the lead with other leads. Do not use defibrillation patch leads with the CRT-D system. Do not use this pulse generator with another pulse generator.

For Patient Triggered Monitor (PTM) feature, make sure the feature is enabled prior to sending the patient home with a magnet. Once the PTM feature has been triggered and the magnet response programming is set to inhibit therapy, the patient should not reapply the magnet.

For DF4-LLHH or DF4-LLHO leads, use caution handling the lead terminal when the Connector Tool is not present on the lead and do not directly contact the lead terminal with any surgical instruments or electrical connections such as PSA (alligator) clips, ECG connections, forceps, hemostats, and clamps. Do not contact any other portion of the DF4-LLHH or DF4-LLHO lead terminal, other than the terminal pin even when the lead cap is in place.

Precautions
For specific information on precautions, refer to the following sections of the product labeling: clinical considerations; sterilization and storage; implantation; device programming; follow-up testing; explant and disposal; environmental and medical therapy hazards; hospital and medical environments; home and occupational environments; and supplemental precautionary information. Advise patients to avoid sources of electromagnetic interference (EMI) because EMI may cause the pulse generator to deliver inappropriate therapy or inhibit appropriate therapy.

Potential Adverse Events
Potential adverse events from implantation of the CRT-D system include, but are not limited to, the following: allergic/physical/physiologic reaction, death, erosion/migration, fibrillation or other arrhythmias, lead or accessory breakage (fracture/insulation/lead tip), hematoma/seroma, inappropriate or inability to provide therapy (shocks/pacing/sensing), infection, procedure related, and component failure. Patients may develop psychological intolerance to a pulse generator system and may experience fear of shocking, fear of device failure, or imagined shocking. In rare cases severe complications or device failures can occur.

Refer to the product labeling for specific indications, contraindications, warnings/precautions and adverse events. Rx only. (Rev. B)

NOTE: Most Current Revision Found @ http://www.bostonscientific.com/cardiac-rhythm-resources/summaries/CRT-D-systems.html

CRT-D Systems from Boston Scientific CRM (COGNIS)

Indications and Usage
These Boston Scientific Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) are indicated for patients with heart failure who receive stable optimal pharmacologic therapy (OPT) for heart failure and who meet any one of the following classifications:
- Moderate to severe heart failure (NYHA Class III-IV) with EF ≤ 35% and QRS duration ≥ 120 ms
- Left bundle branch block (LBBB) with QRS ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class III) ischemic or nonischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure

Contraindications
There are no contraindications for this device.

Warnings
Read the product labeling thoroughly before implating the pulse generator to avoid damage to the system. For single patient use only. Do not reuse, repurpose, or resterilize. Program the pulse generator Tachy Mode to Off during implant, explant or postmortem procedures. Always have sterile external and internal defibrillator protection available during implant and electrophysiologic testing. Ensure that an external defibrillator and medical personnel skilled in CPR are present during post-implant device testing. Advise patients to seek medical guidance before entering environments that could adversely affect the operation of the active implantable medical device, including areas protected by a warning notice that prevents entry by patients who have a pulse generator. Do not expose a patient to MRI scanning. Do not subject a patient with an implanted pulse generator to diathermy. Do not use atrial tracking modes in patients with chronic refractory atrial tachyarrhythmias. Do not use atrial-only modes in patients with heart failure. LV lead dislodgment to a position near the atria can result in atrial oversensing and LV pacing inhibition. Physicians should use medical discretion when implanting this device in patients who present with slow VT. Do not kink, twist or braid the lead with other leads. Do not use defibrillation patch leads with the CRT-D system. Do not use this pulse generator with another pulse generator.

For Patient Triggered Monitor (PTM) feature, make sure the feature is enabled prior to sending the patient home with a magnet. Once the PTM feature has been triggered and the magnet response programming is set to inhibit therapy, the patient should not reapply the magnet.

Precautions
For specific information on precautions, refer to the following sections of the product labeling: clinical considerations; sterilization and storage; implantation; device programming; follow-up testing; explant and disposal; environmental and medical therapy hazards; hospital and medical environments; home and occupational environments; and supplemental precautionary information. Advise patients to avoid sources of electromagnetic interference (EMI) because EMI may cause the pulse generator to deliver inappropriate therapy or inhibit appropriate therapy.

Potential Adverse Events
Potential adverse events from implantation of the CRT-D system include, but are not limited to, the following: allergic/physical/physiologic reaction, death, erosion/migration, fibrillation or other arrhythmias, lead or accessory breakage (fracture/insulation/lead tip), hematoma/seroma, inappropriate or inability to provide therapy (shocks/pacing/sensing), infection, procedure related, and component failure. Patients may develop psychological intolerance to a pulse generator system and may experience fear of shocking, fear of device failure, or imagined shocking. In rare cases severe complications or device failures can occur.

Refer to the product labeling for specific indications, contraindications, warnings/precautions and adverse events. Rx only. (Rev. R)

NOTE: Most Current Revision Found @ http://www.bostonscientific.com/cardiac-rhythm-resources/summaries/CRT-D-systems.html

ADDENDUM TO: 002-1344, Rev. C, US
ICD Systems from Boston Scientific CRM (PUNCTUA, ENERGEN, and INCEPTA)

ICD Indications and Usage
PUNCTUA™, ENERGEN™, and INCEPTA™ ICDs are intended to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias.

Contraindications
Use of these ICD systems are contraindicated in: Patients whose ventricular tachyarrhythmias may have reversible cause, such as 1) digitalis intoxication, 2) electrolyte imbalance, 3) hypoxia, or 4) sepsis, or whose ventricular tachyarrhythmias have a transient cause, such as 1) acute myocardial infarction, 2) electrocution, or 3) drowning. Patients who have a unipolar pacemaker.

Warnings
Read the product labeling thoroughly before implanting the pulse generator to avoid damage to the ICD system. For single patient use only. Do not reuse, reprocess, or resterilize. Program the pulse generator ventricular Tachy Mode to Off during implant, explant or post-mortem procedures. Always have external defibrillator protection available during implant and electrophysiologic testing. Ensure that an external defibrillator and medical personnel skilled in cardiopulmonary resuscitation (CPR) are present during post-implant device testing. Patients should seek medical guidance before entering environments that could adversely affect the operation of the active implantable medical device, including areas protected by a warning notice that prevents entry by patients who have a pulse generator.

For DF4-LLHH or DF4-LLHO leads, use caution handling the lead terminal when the Connector Tool is not present on the lead and do not directly contact the lead terminal with any surgical instruments or electrical connections such as PSA (alligator) clips, ECG connections, forceps, hemostats, and clamps. Do not contact any other portion of the DF4-LLHH or DF4-LLHO lead terminal, other than the terminal pin even when the lead cap is in place.

Precautions
For specific information on precautions, refer to the following sections of the product labeling: clinical considerations; sterilization and storage; implantation; device programming; environmental and medical therapy hazards; hospital and medical environments; home and occupational environments follow-up testing; explant and disposal; supplemental precautionary information. Advise patients to avoid sources of electromagnetic interference (EMI).

Potential Adverse Events
Potential adverse events from implantation of the ICD system include, but are not limited to, the following: allergic/physical/physiologic reaction, death, erosion/migration, fibrillation or other arrhythmias, lead or accessory breakage (fracture/insulation/lead tip), hematomas/seroma, inappropriate or inability to provide therapy (shocks/pacing/sensing), infection, procedure related, psychologic intolerance to an ICD system – patients susceptible to frequent shocks despite antiarrhythmic medical management/imaged/filtered shocking, and component failure. In rare cases severe complications or device failures can occur.

Refer to the product labeling for specific indications, contraindications, warnings/ precautions and adverse events. Rx only. (Rev. B)

NOTE: Most Current Revision Found @ http://www.bostonscientific.com/cardiac-rhythm-resources/summaries/ICD-systems.html

ICD Systems from Boston Scientific CRM (TELIGEN)

ICD Indications and Usage
ICDs are intended to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias. ICDs (i.e. Vitality AVT) with atrial therapies are also intended to provide atrial antitachycardia pacing and atrial defibrillation treatment in patients who have or are at risk of developing atrial tachyarrhythmias.

Contraindications
Use of ICD systems are contraindicated in: Patients whose ventricular tachyarrhythmias may have reversible cause, such as 1) digitalis intoxication, 2) electrolyte imbalance, 3) hypoxia, or 4) sepsis, or whose ventricular tachyarrhythmias have a transient cause, such as 1) acute myocardial infarction, 2) electrocution, or 3) drowning. Patients who have a unipolar pacemaker.

Warnings
Read the product labeling thoroughly before implanting the pulse generator to avoid damage to the ICD system. For single patient use only. Do not reuse, reprocess, or resterilize. Program the pulse generator ventricular Tachy Mode to Off during implant, explant or post-mortem procedures. Always have external defibrillator protection available during implant and electrophysiologic testing. Ensure that an external defibrillator and medical personnel skilled in cardiopulmonary resuscitation (CPR) are present during post-implant device testing. Patients should seek medical guidance before entering environments that could adversely affect the operation of the active implantable medical device, including areas protected by a warning notice that prevents entry by patients who have a pulse generator.

For DF4-LLHO lead, use caution handling the lead terminal when the Connector Tool is not present on the lead and do not directly contact the lead terminal with any surgical instruments or electrical connections such as PSA (alligator) clips, ECG connections, forceps, hemostats, and clamps. Do not contact any other portion of the DF4-LLHH or DF4-LLHO lead terminal, other than the terminal pin even when the lead cap is in place.

Precautions
For specific information on precautions, refer to the following sections of the product labeling: clinical considerations; sterilization and storage; implantation; device programming; environmental and medical therapy hazards; hospital and medical environments; home and occupational environments follow-up testing; explant and disposal; supplemental precautionary information. Advise patients to avoid sources of electromagnetic interference (EMI).

Potential Adverse Events
Potential adverse events from implantation of the ICD system include, but are not limited to, the following: allergic/physical/physiologic reaction, death, erosion/migration, fibrillation or other arrhythmias, lead or accessory breakage (fracture/insulation/lead tip), hematomas/seroma, inappropriate or inability to provide therapy (shocks/pacing/sensing), infection, procedure related, psychologic intolerance to an ICD system – patients susceptible to frequent shocks despite antiarrhythmic medical management/imaged/filtered shocking, and component failure. In rare cases severe complications or device failures can occur.

Refer to the product labeling for specific indications, contraindications, warnings/ precautions and adverse events. Rx only. (Rev. Q)

NOTE: Most Current Revision Found @ http://www.bostonscientific.com/cardiac-rhythm-resources/summaries/ICD-systems.html

ADDENDUM TO: 002-1344, Rev. C, US